Rocket Pharmaceuticals
RCKT
Performance
About Rocket Pharmaceuticals
Rocket Pharmaceuticals is a biopharmaceutical company focused on developing gene and molecular therapies to treat rare genetic diseases, with a particular emphasis on cardiac and other organ-specific conditions. The company conducts research and clinical trials globally, including programs for Danon disease and other rare cardiovascular disorders, with corporate and R&D headquarters in Cranbury, New Jersey and presence in New York. Their work aims to move gene therapies from research to approved treatments that address root causes of disease and improve patient outcomes. They also emphasize patient resources and collaboration with healthcare professionals and regulatory bodies to advance rare-disease therapeutics.
Recent News
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
FDA Turmoil Casts Shadow Over Gene‑Therapy Conference in Rome
FDA Grants First Gene‑Therapy Approval for Rare Pediatric Immune Disorder LAD‑I
Weekly Reads: 1st FDA-Approved CIRM Supported Therapy, Asymmetric Histone Inheritance, Stem Cell Retraction
Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher
Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Rocket to Sell PRV for $180m to Advance Gene Therapy Pipeline
Rocket Pharmaceuticals Secures $180 Million From Priority Review Voucher Sale
STAT+: Even at a Meeting in Rome, FDA Shifts Are Top of Mind for Gene Therapy Field
Opinion: Prasad’s FDA Exit Good for Rare Diseases but New CBER Head Must Repair Eroded Trust
From Awareness to Acceleration: Rare Disease Drug Development Enters a Pivotal Era
JPM Day 3: Rare Disease in the Spotlight
FDA Approves Rocket's Kresladi, First Gene Therapy for Ultra‑Rare LAD‑1
Recent Deals
No recent deals for this company.